Phillip Kempf
Rheumatology · Arlington, VANPI 1386662286
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $232,348 of the $321,283 with a category attached, or 72.3%. It is spread thinly across 33 manufacturers, the largest accounting for just 20.2%. Reporting peaked in 2019 at $130,243 and has fallen 91.7% since, to $10,848 in 2024. Among rheumatology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,179 payments — averaging $272.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$65K
- Mallinckrodt Hospital Products Inc.$59K
- UCB, Inc.$54K
- Amgen$49K
- AstraZeneca$17K
- Pfizer$15K
- plus $63K from 27 others
Across 54 payments — averaging $2726.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$66K
- AbbVie$42K
- GSK$22K
- E.r. Squibb & Sons, L.L.C.$8K
- Aurinia Pharma U.S., Inc.$8K
- Janssen Research & Development, LLC$2K
What the payments were for
- Consulting fees$35,32211%
- Speaking & faculty fees$232,34872%
- Travel & lodging$27,5599%
- Food & beverage$25,8288%
- Education$1860%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 167 | $64,960 |
| Mallinckrodt Hospital Products Inc. | 90 | $59,004 |
| UCB, Inc. | 189 | $54,077 |
| Amgen(2 entities) | 186 | $48,535 |
| AstraZeneca(2 entities) | 56 | $16,573 |
| Pfizer | 59 | $15,383 |
| Bristol Myers Squibb | 43 | $14,334 |
| Mallinckrodt Enterprises LLC | 23 | $14,018 |
| GSK | 43 | $9,022 |
| E.r. Squibb & Sons, L.L.C. | 19 | $5,040 |
| Regeneron Healthcare Solutions, Inc. | 20 | $4,797 |
| Johnson & Johnson(2 entities) | 122 | $4,078 |
| Ultragenyx Pharmaceutical Inc. | 5 | $3,952 |
| ANI Pharmaceuticals, Inc. | 23 | $3,007 |
| Avion Pharmaceuticals | 1 | $1,460 |
| Lilly USA, LLC | 47 | $1,118 |
| Novartis | 37 | $814 |
| Aurinia Pharma U.S., Inc. | 10 | $228 |
| Genentech USA, Inc. | 7 | $138 |
| Fresenius Kabi USA, LLC | 4 | $94 |
| Bioventus LLC | 4 | $91 |
| Sanofi | 4 | $91 |
| Boehringer Ingelheim | 3 | $89 |
| Pacira Therapeutics, Inc. | 2 | $83 |
| Organon | 3 | $58 |
| Hikma Pharmaceuticals USA | 3 | $49 |
| Sobi, Inc | 2 | $45 |
| Fidia Pharma USA Inc. | 2 | $40 |
| Medtronic | 1 | $34 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Zyla Life Sciences, Inc. | 1 | $17 |
| Ascend Therapeutics US, LLC | 1 | $17 |
| Sandoz | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$321,283 in reported general payments places this provider in the 95th percentile of 159 rheumatology providers in Virginia.
Other rheumatology in Arlington
- Peter LipskyCharlottesville$1.3M
- Kristi MizelleNewport News$1.1M
- Sharukh ShroffDanville$216K
- Michael StrachanRichmond$158K
- Karim MasriRichmond$147K
- Michael CannonVirginia Beach$145K
- Phong NguyenReston$127K
- Chase CorreiaHampton$70K
- Alexia GospodinoffReston$27K
- Donald KimpelCharlottesville$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.